Phase 1 Clinical Trial Commences for [11C]ZTP-1, a PET Tracer Specific to PDE4B
![Phase 1 Clinical Trial Commences for [11C]ZTP-1, a PET Tracer Specific to PDE4B](/_next/image?url=https%3A%2F%2Fkftqdoaulkufffpdoijc.supabase.co%2Fstorage%2Fv1%2Fobject%2Fpublic%2Fbio-news-images%2Fnews_09414ad1.jpg&w=3840&q=75)
Research Background
PDE4B is an enzyme that terminates specific signaling pathways within cells and is involved in inflammation, immune responses, and brain signal transduction. Direct measurement of PDE4B levels in the body can aid in understanding disease states and monitoring treatment efficacy.
Clinical Design
This Phase 1 clinical trial, sponsored by the National Institute of Mental Health (NIMH), will be conducted from June 15, 2026, on healthy adults (18 years and older). Participants will attend 1-2 visits, during which they will undergo a PET/CT scan and blood, urine, and cardiac function tests before the scan. The radioactive tracer [11C]ZTP-1 will be administered intravenously, and participants will lie on a padded bed during the scan.
Expected Outcomes
If [11C]ZTP-1 proves to be safe and accurately visualizes PDE4B distribution, it has the potential to be used as a biomarker in future research on inflammatory and neurological diseases.
From an investor's perspective, the successful development of a PDE4B-specific PET tracer under the sponsorship of NIMH could lead to first-mover advantages and licensing revenue in the imaging biomarker market. For job seekers or professionals looking to enter the field of imaging diagnostics, staying informed about the latest tracer research trends and enhancing their expertise can significantly improve their competitiveness.
Source: ClinicalTrials.gov (api_ct)